Grey Nuns Community Hospital, Edmonton, Alberta, Canada (Dr Chokka); H. Lundbeck A/S, Valby, Denmark (Mr Tvistholm, Dr Ettrup); and Lundbeck Canada Inc., Montreal, Quebec, Canada (Dr Bougie, Dr Clerzius).
J Occup Environ Med. 2020 Mar;62(3):e94-e101. doi: 10.1097/JOM.0000000000001805.
To assess changes in workplace productivity and functioning in an open-label study in working patients receiving vortioxetine (10 to 20 mg/d) for major depressive disorder (MDD).
Associations between items in the Work Limitations Questionnaire (WLQ), the Sheehan Disability Scale (SDS), and the Work Productivity and Activity Impairment (WPAI) questionnaire were assessed at 12 and 52 weeks by Pearson correlation coefficients.
Significant improvements were observed across all domains of workplace productivity and functioning after 12 and 52 weeks' vortioxetine treatment. Strong correlations were seen between improvements in WLQ mental domains and WPAI presenteeism and SDS work/school items. Presenteeism showed stronger correlations with other workplace productivity measures than absenteeism.
Presenteeism and absenteeism impact productivity in working patients with MDD. Vortioxetine confers long-term benefits across all workplace functioning domains.
在一项开放性标签研究中评估工作的抑郁症患者接受文拉法辛（10 至 20 毫克/天）治疗后，工作场所生产力和功能的变化。
通过 Pearson 相关系数评估工作限制问卷（WLQ）、Sheehan 残疾量表（SDS）和工作生产力和活动障碍（WPAI）问卷在 12 周和 52 周时各项目之间的相关性。
文拉法辛治疗 12 周和 52 周后，所有工作场所生产力和功能领域均有显著改善。WLQ 精神领域的改善与 WPAI 出席率和 SDS 工作/学校项目之间存在较强相关性。出席率与其他工作场所生产力衡量标准的相关性强于旷工。
工作中的抑郁症患者的旷工和出席率会影响生产力。文拉法辛在所有工作场所功能领域都带来了长期的益处。
